Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack prevention revolution? CT scan may beat standard risk scores

NCT ID NCT03920176

Prevention Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways to prevent heart attacks in people at risk: a CT scan of the heart arteries versus the usual risk score method. About 6,139 adults aged 40-70 with risk factors like high blood pressure, diabetes, or smoking are involved. The goal is to see if the CT-guided approach reduces deaths from heart disease and non-fatal heart attacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6,139 people

The number who actually took part.

Started

Jan 2020

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA * ≥40 and ≤70 years of age * Resident in Scotland and have a Community Health Index (CHI) number * One or more of the following risk factors: * \>60 years of age * Current or recent (within 12 months) smoker * Clinical diagnosis of hypertension * Known hypercholesterolaemia or total cholesterol \>6.0 mmol/L or receiving statin therapy * Diabetes mellitus * Rheumatoid arthritis * Systemic lupus erythematosus (SLE) * Family history of premature cardiovascular disease (first degree relative with atherosclerotic cardiovascular disease below 60 years) * Chronic kidney disease stage 3 (estimate glomerular filtration rate 30-59 mL/min/1.73 m2). EXCLUSION CRITERIA * Inability to undergo CTCA * Known coronary heart disease or other major atherosclerotic cardiovascular disease * Prior invasive or non-invasive coronary angiography within the last 5 years * Chronic kidney disease stage ≥4 (estimate glomerular filtration rate \<30 mL/min/1.73 m2) * Known homozygous familial hypercholesterolaemia or other serious inherited disorders of lipid metabolism requiring statin therapy * Intolerance of all statins * Statin therapy for \>2 years. * Previous coronary artery imaging completed specifically for cardiovascular risk assessment with a result of \>10 AU.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder myocardial infarction prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases

Contacts and locations

Locations

  • Western General Hospital

    Edinburgh, City Of Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.